Qiagen further invests in cancer Dx portfolio with Ipsogen buy
This article was originally published in Clinica
Qiagen is set to acquire Ipsogen, a French specialist in blood cancers diagnostics, in a deal worth $101m. The move, which follows a flurry of investments made by the Dutch firm over the last few months, underlines its strategy to build critical mass in the molecular diagnostics field.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.